|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM11318655X |
003 |
DE-627 |
005 |
20231222163343.0 |
007 |
tu |
008 |
231222s2001 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0378.xml
|
035 |
|
|
|a (DE-627)NLM11318655X
|
035 |
|
|
|a (NLM)11414742
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Tassignon, J
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Azodicarbonamide as a new T cell immunosuppressant
|b synergy with cyclosporin A
|
264 |
|
1 |
|c 2001
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 16.08.2001
|
500 |
|
|
|a Date Revised 08.12.2020
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright 2001 Academic Press.
|
520 |
|
|
|a We recently demonstrated that azodicarbonamide is an immunosuppressive compound that inhibits calcium mobilization in T lymphocytes. In this study, we show that azodicarbonamide prevents the progression of human CD4+ T lymphocytes into the G1 phase of the cell cycle, inhibits their blastogenesis, down-regulates their membrane expression of CD25 and CD69, and decreases their transcription of cytokine genes. Addition of the calcium ionophore A23187 completely restores T cell proliferation in the presence of azodicarbonamide. Furthermore, azodicarbonamide synergizes with cyclosporin A to inhibit CD4+ T cell proliferation. In conclusion, the immunosuppressive action of azodicarbonamide is mainly related to its effect on the calcium mobilization machinery and is synergistic with that of calcineurin inhibitors
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Antigens, CD
|2 NLM
|
650 |
|
7 |
|a Antigens, Differentiation, T-Lymphocyte
|2 NLM
|
650 |
|
7 |
|a Azo Compounds
|2 NLM
|
650 |
|
7 |
|a CD69 antigen
|2 NLM
|
650 |
|
7 |
|a Calcineurin Inhibitors
|2 NLM
|
650 |
|
7 |
|a DNA-Binding Proteins
|2 NLM
|
650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
650 |
|
7 |
|a Interleukin-2
|2 NLM
|
650 |
|
7 |
|a Ionophores
|2 NLM
|
650 |
|
7 |
|a Lectins, C-Type
|2 NLM
|
650 |
|
7 |
|a NFATC Transcription Factors
|2 NLM
|
650 |
|
7 |
|a Nuclear Proteins
|2 NLM
|
650 |
|
7 |
|a Receptors, Interleukin-2
|2 NLM
|
650 |
|
7 |
|a Transcription Factors
|2 NLM
|
650 |
|
7 |
|a Calcimycin
|2 NLM
|
650 |
|
7 |
|a 37H9VM9WZL
|2 NLM
|
650 |
|
7 |
|a azodicarbonamide
|2 NLM
|
650 |
|
7 |
|a 56Z28B9C8O
|2 NLM
|
650 |
|
7 |
|a Cyclosporine
|2 NLM
|
650 |
|
7 |
|a 83HN0GTJ6D
|2 NLM
|
700 |
1 |
|
|a Vandevelde, M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Goldman, M
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 100(2001), 1 vom: 10. Juli, Seite 24-30
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:100
|g year:2001
|g number:1
|g day:10
|g month:07
|g pages:24-30
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 100
|j 2001
|e 1
|b 10
|c 07
|h 24-30
|